The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines - Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch. - BioPharm

ADVERTISEMENT

The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines
Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch.


BioPharm International



Figure 2. Dose sparing in the guinea pig model using rH5 (Anti-A/Vietnam/1203/2004). Animals received two intradermal injections 21 days apart of either 0.001, 0.01, 0.1, 1, or 10 μg rHA and an IS patch containing either 10 μg LT or a placebo with no LT at the time of second injection. Serum IgG titers were determined by an ELISA method two weeks after the final immunization. Results of individual animals (5–6 per group, open circles) and the group geomeans (bars) are shown.
An additional preclinical study was conducted in guinea pigs using the same H5N1 rHA antigen in doses ranging from 0.001–10 μg. Both IM and ID routes were used in a two-dose prime/boost regimen. Animals received an IS patch containing 10 μg of LT or a placebo patch at the time of boost. A 10-fold dose sparing was observed using the LT-IS patch for the IM route (data not shown), and ≥10-fold using the ID route (Figure 2). Taken together, the preclinical data in both animal models show that the LT-IS patch can dose spare 10– to 100–fold.

Universal Adjuvant Effect for Seasonal Flu Vaccines


Figure 3. IS patch effect of different seasonal flu vaccines in the mouse. Mice received two intradermal immunizations, 14 days apart, of a commercially available seasonal flu vaccine and IS patches containing either 10 μg LT or a placebo with no LT. Serum IgG titers were determined by an ELISA method. Results of individual animals (8 per group, open circles) and the group geomeans (bars) are shown. Groups receiving LT have statistically greater titers than groups receiving placebo patches.
We also evaluated the LT-IS patch effect using different manufacturers' influenza vaccines and demonstrated that the adjuvant effect is not antigen-dependent. Four commercial annual vaccines were evaluated: FluShield, Fluzone, Fluvirin, and InFlexal. Trivalent influenza vaccine at 4.5 μg HA dose per virus strain was injected ID into mice with and without an LT-IS patch (10 μg LT). The mice were immunized twice, two weeks apart, with serum collection two weeks after the second immunization. The animals receiving the LT-IS patches had significantly higher anti-influenza IgG titers (as determined by ELISA) than those receiving flu vaccines with placebo patches (no LT). Only anti-A/New Caledonia serum IgG titers are shown in Figure 3 as representative of IgG response in all three strains. Figure 3 indicates that influenza vaccines obtained from different manufacturers were enhanced equivalently with an LT-IS patch and reinforces the idea of a potential universal dose sparing strategy using an LT-IS patch.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here